Connect live...

Select the exhibitor's booth below and get connected live.

Click on "Edit" in the right panel to replace this with your own HTML code

Other exhibitors

Entrepreneur

Soon Crypto Investing Automated & Easy
Entrepreneur

Digital Asset Management A coin for the future of crypto Investing
Entrepreneur

Nutr Changing the way we milk
Entrepreneur

Adlore Introducing SenLore - A Novel Device to Treat and Monitor Diabetic Foot Ulcers
Entrepreneur

Torque3 Transformative Stroke Recovery
Entrepreneur

SeekingSimple "Improved health through better processed food choices to address food related disease for 230M in the US and the resulting $1.1T problem for healthcare payors"
Entrepreneur

Gel Dynamics The only fully dynamic and continuous wheel balancing solution destined to reshape the trucking industry while contributing to a greener planet.
Entrepreneur

Kurve Therapeutics The Future of Systemic and Central Nervous System (CNS) Therapies - Bringing solutions to clinical unmet needs
Entrepreneur

Schmaltz Restaurant Group Spread Jewish Deli Goodness Everywhere
Information

iCFO Information Booth How can we help?
Entrepreneur

Nob Hill Therapeutics Pioneering Respiratory Patient Care
Entrepreneur

Welton Pharma Welton is utilizing Apisolex drug delivery technology to optimize pharmaceutical drug products
Entrepreneur

STRATAFOLIO Total Commercial Property Management Platform
Entrepreneur

PROOF Hard Ice Cream PROOF will be among the most highly recommended gourmet brands in the world
Entrepreneur

Opus Genetics Envisioning a new future for patients with inherited retinal diseases

Event DealConnect 360: The Ultimate Deal Room for Real Results! is over.
Join us next time to meet Artur Plonowski!

About Vasa Therapeutics

Vasa Therapeutics

Novel therapeutics for unmet medical needs in cardiovascular medicine

Available from 12:00 PM - 4:00 PM (US/Pacific)

http://www.vasatherapeutics.com

aplonowski@vasatherapeutics.com

+1 408-410-1159

Vasa Therapeutics addresses significant unmet medical needs in cardiovascular and metabolic medicine: heart failure, obesity, sarcopenia, peripheral artery disease, and life-threatening arrhythmias. The company has developed an attractive pipeline of projects with validated mechanisms of action and strong biomarker support. The company is led by a highly experienced management team with a track record of drug development and strategic partnerships. In addition to the current series seed, the company is pursuing non-dilutive funding opportunities through grants ($2.3M awarded to date) and potential strategic partnerships at the pre-clinical stage.